Compare LNTH & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | RGEN |
|---|---|---|
| Founded | 1956 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.6B |
| IPO Year | 2014 | 1995 |
| Metric | LNTH | RGEN |
|---|---|---|
| Price | $102.09 | $115.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $87.00 | ★ $167.67 |
| AVG Volume (30 Days) | 948.2K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | ★ 1.80 | 0.15 |
| Revenue | ★ $343,374,000.00 | $141,236,000.00 |
| Revenue This Year | N/A | $14.30 |
| Revenue Next Year | $14.19 | $14.52 |
| P/E Ratio | ★ $52.74 | $765.23 |
| Revenue Growth | 3.62 | ★ 35.10 |
| 52 Week Low | $47.27 | $100.99 |
| 52 Week High | $98.27 | $175.77 |
| Indicator | LNTH | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 72.99 | 49.58 |
| Support Level | $72.35 | $111.09 |
| Resistance Level | N/A | $129.77 |
| Average True Range (ATR) | 3.29 | 5.93 |
| MACD | 0.23 | 0.35 |
| Stochastic Oscillator | 88.45 | 46.89 |
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.